Sallman, D. A., Komrokji, R. S., Dezern, A. E., Sebert, M., Garcia‐Manero, G., Rahmé, R., . . . Cluzeau, T. Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML. Wiley.
Chicago Style (17th ed.) CitationSallman, David A., et al. Long‐term Follow‐up and Combined Phase 2 Results of Eprenetapopt and Azacitidine in Patients with TP53 Mutant MDS/AML. Wiley.
MLA (9th ed.) CitationSallman, David A., et al. Long‐term Follow‐up and Combined Phase 2 Results of Eprenetapopt and Azacitidine in Patients with TP53 Mutant MDS/AML. Wiley.
Warning: These citations may not always be 100% accurate.